Form 8-K · Current Report · Filed 2025-02-24
Crinetics Pharmaceuticals Appoints New CFO, Schilke
Crinetics Pharmaceuticals, Inc. announced on February 24, 2025, the appointment of Tobin 'Toby' Schilke as Chief Financial Officer, effective February 28, 2025. Schilke, a seasoned biopharma executive with over 25 years of global pharmaceutical experience, previously served as CFO at Revance Therapeutics and Achaogen. Marc Wilson, the outgoing CFO, is stepping down for personal reasons. Schilke will be granted 52,000 restricted stock units and a stock option for 80,000 shares as part of his employment agreement.
- Filer
- Crinetics Pharmaceuticals Inc. CRNX · NASDAQ
- Filed
- Accession
- 0000950170-25-025248
- CIK
- 0001658247
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Regulation FD Disclosure
Financial Statements and Exhibits
Market reaction
Close before filing
$37.46
Next session
-13.8%
Since filing
+123.0%
Latest close
$83.52
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from CRNX reporting the same item, with the next session's move:
Exhibits (1)
About Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development of novel therapeutics for patients with endocrine conditions and other rare diseases. The primary focus of Crinetics is on crafting oral therapies that target hormone receptors, offering significant potential to transform the treatment landscape for several disorders. The company's pipeline includes investigational drugs such as paltusotine and CRN04894, aimed at addressing conditions like acromegaly and congenital adrenal hyperplasia, respectively. Crinetics combines cutting-edge drug discovery with an in-depth understanding of disease biology to impact the field of endocrinology substantially. By specializing in small molecules, Crinetics Pharmaceuticals seeks to provide new treatment options that enhance patient quality of life and address significant unmet medical needs. Headquartered in San Diego, California, the enterprise collaborates with academic institutions and industry partners to position its innovations at the forefront of medical advancement. Its work holds significant potential to influence the pharmaceutical industry, contributing to the expansion of targeted therapies within niche markets where few options currently exist.
Never miss another CRNX filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.